Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$0.1.

  • Heron Therapeutics' EPS (Basic) fell 23333.33% to -$0.1 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.08, marking a year-over-year increase of 5000.0%. This contributed to the annual value of -$0.09 for FY2024, which is 8851.26% up from last year.
  • Latest data reveals that Heron Therapeutics reported EPS (Basic) of -$0.1 as of Q3 2025, which was down 23333.33% from -$0.02 recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' EPS (Basic) ranged from a high of $0.03 in Q4 2024 and a low of -$0.63 during Q1 2022
  • Moreover, its 5-year median value for EPS (Basic) was -$0.17 (2023), whereas its average is -$0.26.
  • The largest annual percentage gain for Heron Therapeutics' EPS (Basic) in the last 5 years was 20000.0% (2025), contrasted with its biggest fall of 23333.33% (2025).
  • Quarter analysis of 5 years shows Heron Therapeutics' EPS (Basic) stood at -$0.53 in 2021, then surged by 75.47% to -$0.13 in 2022, then skyrocketed by 61.54% to -$0.05 in 2023, then surged by 154.75% to $0.03 in 2024, then plummeted by 465.32% to -$0.1 in 2025.
  • Its EPS (Basic) stands at -$0.1 for Q3 2025, versus -$0.02 for Q2 2025 and $0.02 for Q1 2025.